

June 22, 2011
AnGes MG, Inc.

Substance Patent for Novel Peptide Granted in Japan
- A Patent Covering Polypeptide Having Both Angiogenic and Antimicrobial Activity -

AnGes MG, Inc. and its subsidiary, GenomIdea, Inc. are pleased to announce that the substance patent for a novel peptide was granted in Japan and the Patent Gazette was issued today (patent No. 4705026).

AnGes MG is already developing products from the functional peptide “Cure-Peptin®”, which has a broad antibacterial spectrum and also exerts effects against multiple-drug-resistant bacteria that have become a major problem as the source of nosocomial infections. The present invention is included in a series with “Cure-Peptin®” and will further expand targets for development.

Regarding the polypeptide (AG-30) related to the present invention, researchers at Osaka University have already published papers which present its pharmacological activities in detail (e.g. The Journal of Japanese College of Angiology, 2008, volume 48: 437 - 440). This polypeptide is characterized by having both angiogenic and antimicrobial activity in a well-balanced manner.

In general, polypeptides are easily broken down in the body, and it is difficult to administer them systemically, such as by oral or intravenous administration. Consequently, there has been no precedent success in their clinical development.

However, for external medications that can be topically administered to the skin or other region, there is less concern about the polypeptides being broken down. Therefore commercialization of the remarkable characteristics of this polypeptide (AG-30), which is the present invention, is expected to take place.

Concretely, the promotion of blood flow based on angiogenesis and the prevention of infections or disinfection based on antimicrobial activity are major factors to promote healing of affected sites, such as bedsores, wounds, and skin ulcers. In the past it was necessary for two agents which have respective pharmacological activities to be administered simultaneously. However, simultaneous administration of two agents is a complex process, and also involves the problem of increase in medical costs. In this context, there have been demands for a new single agent which exerts both activities in a well-balanced manner.

The application of this patent was made by GenomIdea and its exclusive license was obtained by AnGes MG.

This patent is valid until March 2025. It is registered as US4705026 and is also protected until March 2025 in the US. It is currently patent pending in Europe.

AnGes MG group aims to expand the application of novel polypeptides to various unmet needs by taking advantage of their characteristics and long-term patent protection.

This trend will have no effect on AnGes MG’s business performance for the current fiscal year.